Vadimezan - Wikipedia, the free encyclopedia
Vadimezan or ASA404
is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.
Novartis Oncology Research: ASA404 For Lung Cancer
Read information about ASA404
, a Novartis Oncology investigational cancer treatment that disrupts established tumor vasculature, inhibiting tumor blood flow and ...
ASA404 Vascular Disrupting Agent for Solid Tumours - Drug Development ...
Project on the ASA404
vascular disrupting agent for solid tumours by Antisoma and Novartis. ... Novartis subsequently acquired worldwide rights to ASA404
in 2007. ...
Positive data on Antisoma's ASA404 presented at ASCO | Reuters
LONDON, UK, Jun 01 (MARKET WIRE) -- London, UK, and Chicago, IL, 1 June 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that two presentations supporting ASA404
starting a Phase III trial for the drug, ASA404ASA404
... Novel mechanism of action of ASA404
disrupts existing blood supply to tumors ... ASA404
is one of six novel oncology compounds Novartis is developing for ...
ATTRACT Clinical Trial – Antivascular Targeted Therapy: Researching ...
Learn about ATTRACT clinical trial from Novartis Oncology, and investigational cancer treatment: Antivascular Targeted Therapy: Researching ASA404
in Cancer Treatment.